Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

CiteSentinel Launched to Detect and Prevent AI Hallucinations in Legal Citations

Published

on

Legal tech startup BrentWorks reports that it has launched CiteSentinel, a dedicated platform built specifically to detect and prevent AI hallucinations in legal citations, including those related to biotechnology. The tool scans legal documents and flags case law, statutes, and legal authorities that may be fabricated, misstated, or otherwise erroneous, before they reach a judge, according to the company.

Courts across the country are increasingly sanctioning attorneys who submit briefs containing invented case citations, a well-documented byproduct of generative AI drafting tools that produce authoritative-sounding, but entirely fictional, legal authority, says BrentWorks co-founder Brent Britton, a technology attorney and MIT-trained engineer. CiteSentinel was designed to close that verification gap, giving attorneys a fast and easy way to confirm that every citation in a filing corresponds to a real case, a real statute, and a real legal authority, he adds.

“The legal profession is learning, in very public ways, that AI doesn’t just make mistakes, it confidently lies to your face,” continues Britton. “CiteSentinel is about restoring trust. It lets lawyers move fast with the irresistible efficiencies of generative AI while still filing documents reciting authorities they can stand behind. It also enables them to scan opposing counsel’s documents, giving them a competitive edge in the courtroom.”

AI hallucinations
When a brief containing fabricated citations reaches the court, the question of who drafted it quickly becomes secondary to the question of whose name is on it. [BestForBest/Getty Images]

Many attorneys who do not personally use AI to draft documents are discovering they have a problem anyway, Britton points out. Opposing counsel may have used AI. Co-counsel may have. Contract attorneys and paralegals almost certainly have access to it and may be using it without disclosing that fact. When a brief containing fabricated citations reaches the court, the question of who drafted it quickly becomes secondary to the question of whose name is on it, he explains.

CiteSentinel lets attorneys scan any document, their own, a colleague’s, or an adversary’s, for citation errors before those errors become their problem, notes Britton. Attorneys who review opposing counsel’s filings with CiteSentinel gain an additional advantage: the ability to identify and challenge citations to authorities that simply do not exist, he says.

Unlike traditional research platforms that focus on finding more information, states Britton, CiteSentinel was created to confirm that the law cited in a document is real. Attorneys can scan:

  • Their own AI-assisted drafts, before filing
  • Submissions from co-counsel, contract attorneys, and support staff
  • Opposing counsel’s filings, for strategic advantage
  • Any document where citation accuracy carries professional or ethical weight

BrentWorks’ other co-founder is Brent Hunter, a technologist who applied neural networks to finance in 1993. He cites CiteSentinel as the first in a series of products the company will be releasing for the practice of law in the age of AI.

Both BrentWorks’ co-founders agree that AI hallucinations pose particular risks in biotechnology-related legal matters because cases often depend on highly technical evidence, including patent claims, prior art, clinical trial data, FDA regulatory history, scientific publications, expert witness testimony, freedom-to-operate analyses, and licensing agreements. In this context, an AI system could invent scientific references that do not exist, mischaracterize FDA guidance documents, fabricate patent precedents, incorrectly summarize clinical trial results, or generate inaccurate prior-art searches. Such errors can undermine legal arguments, regulatory submissions, and intellectual property strategies.

“Biotech litigation is where AI hallucinations turn genuinely dangerous. You have a system trained to sound authoritative now injecting phantom patent precedents and counterfeit clinical data into documents that determine whether a drug reaches patients or a patent survives challenge,” explains Brent Britton. “In this domain, where the technical record is everything, a ghost FDA guidance document or a fabricated prior art reference can unravel an entire legal strategy and years of work along with it. The law has always been a high-stakes information game, and right now the machines are playing it with synthetic cards.”

As CiteSentinel expands beyond just case citation verification, “it will be the truth layer that keeps all players honest,” he predicts.

 

The post CiteSentinel Launched to Detect and Prevent AI Hallucinations in Legal Citations appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read